Abstract
NeuroAIDS is a neuropsychiatric disorder primarily caused by chronic human immunodeficiency virus (HIV). The most common neurological complications during NeuroAIDS are HAD (HIV-associated dementia) and HAND (HIV-associated neurocognitive disorder). HAART (highly active antiretroviral therapy) is a group of ARV (antiretroviral) drugs used to inhibit the key proteins involved in HIV replication. ARV drugs are extensively used to decrease the viral load and risk of opportunistic infections and to prolong survival of HIV-infected individuals. Significant advancement in antiretroviral (ARV) drugs has been achieved. However, the elimination of HIV from the CNS remains a difficult task. The complex structure of blood-brain barrier (BBB), high plasma protein binding, low patient compliance, and poor pharmacokinetics and biodistribution are the major limitations which restrict the effective concentration of drug to the CNS resulting in low efficacy of HAART in the CNS. Development of novel nanotechnology-based drug delivery methods for ARV drugs can increase the effectiveness of regimen with fewer side effects and better patient compliance which reduces financial load of healthcare system. The present article discusses about the nanotechnology-based approaches that can improve the delivery of ARV, called nano-ART. Nano-ART has excellent BBB permeability and improved pharmacokinetics and biodistribution that have significant clinical advantages to cure the CNS infection of HIV.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- HIV:
-
Human immunodeficiency virus
- HAND:
-
HIV-associated neurocognitive disorders
- CNS:
-
Central nervous system
- ARV:
-
Antiretroviral
- ART:
-
Antiretroviral therapy
- BBB:
-
Blood-brain barrier
- HAD:
-
HIV-associated dementia
- HAART:
-
Highly active antiretroviral therapy
- SLN:
-
Solid lipid nanoparticles
- MNP:
-
Magnetic nanoparticles
References
Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M (2010) Strategy for effective brain drug delivery. Eur J Pharm Sci 40(5):385–403
Bain LE, Nkoke C, Noubiap JJN (2017) UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on “Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades”. BMJ Glob Health 2(2):e000227
Batrakova EV, Gendelman HE, Kabanov AV (2011) Cell-mediated drug delivery. Expert Opin Drug Deliv 8:415–433
Bondì ML, Di Gesù R, Craparo EF (2012) Lipid nanoparticles for drug targeting to the brain. Methods Enzymol 508:229–251
Das MK, Sarma A, Chakraborty T (2016) Nano-ART and NeuroAIDS. Drug Deliv Transl Res 6(5):452–472
Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA (2010) Antiretroviral release from poly (DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother 65(10):2183–2187
Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J (2009) Macrophage delivery of nanoformulated anti-retroviral drug to the brain in a murine model of Neuro-AIDS. J Immunol 183(1):661–669
Dutta T, Jain NK (2007) Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. BiophysActa 1770:681–686
Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D, UK Collaborative Group on HIV Drug Resistance (2009) Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 48(9):1296–1305
Gorantla S, Dou H, Boska M (2006) Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol 80(5):1165–1174
Häggblom A, Svedhem V, Singh K, Sönnerborg A, Neogi U (2016) Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. Lancet HIV 3(4):e166–e174
Heiati H, Tawashi R, Shivers RR, Phillips NC (1997) Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. Int J Pharm 146(1):123–131
Hemelaar J (2012) The origin and diversity of the HIV-1 pandemic. Trends Mol Med 18(3):182–192
Jayant RD, Atluri VSR, Agudelo M, Sagar V, Kaushik A, Nair M (2015) Sustained-release Nano-ART formulation for the treatment of Neuro-AIDS. Int J Nanomedicine 10:1077–1093
Kabanov AV, Gendelman HE (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 32(8–9):1054–1082
Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA (2005) HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12:878–892
Kaushik A, Jayant RD, Nair M (2016) Advancements in nano-enabled therapeutics for neuroHIV management. Int J Nanomedicine 11:4317–4325
Kaushik A, Jayant RD, Nair M (2018) Nanomedicine for neuroHIV/AIDS management. Nanomedicine (Lond) 13(7):669–673
Kim S, Scheerer S, Geyer MA, Howell SB (1990) Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J Infect Dis 162:750–752
Kumar S, Maurya VK, Dandu HR, Bhatt ML, Saxena SK (2018) Global perspective of novel therapeutic strategies for the management of NeuroAIDS. Biomol Concepts 9(1):33–42
Kuo YC (2005) Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate- sulfopropylmethacrylate copolymer nanoparticles. Int J Pharm 290:161–172
Kuo Y-C, Su F-L (2007) Transport of stavudine, delavirdine, and saquinavir across the blood–brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 340(1–2):143–152
Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL (2010) HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 5(3):294–309
Mallipeddi R, Rohan LC (2010) Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine 5:533–547
Maurya VK, Kumar S, Saxena SK (2018) Molecular mechanism of neuropathogenesis and current therapeutics for neuroAIDS. Res Rep 1:e1–e8
McCombe JA, Noorbakhsh F, Buchholz C, Trew M, Power C (2009) NeuroAIDS: a watershed for mental health and nervous system disorders. J Psychiatry Neurosci 34(2):83–85
Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti P, Nagarkatti M, Chauhan A (2010) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5(6):e11160
Mehta SK, Jindal N (2015) Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine. AAPS PharmSciTech 16(1):67–75
Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S (2013) Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun 4:1707
Nair M, Jayant RD, Kaushik A, Sagar V (2016) Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev 103:202–217
Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R (2018) The HIV-1 tat protein affects human CD4+ T-cell programming and activation, and favors the differentiation of naïve CD4+ T cells. AIDS 32(5):575–581
Nowacek A, Gendelman HE (2009) NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) 4(5):557–574
Pant M, Garg P, Seth P (2012) Central nervous system infection by HIV-1: special emphasis to NeuroAIDS in India. Proc Natl Acad Sci India Sect B 82(1):81–94
Peng J, Wu Z, Qi X, Chen Y, Li X (2013) Dendrimers as potential therapeutic tools in HIV inhibition. Molecules 18:7912–7929
Rahimian P, He JJ (2017) HIV/neuroAIDS biomarkers. Prog Neurobiol 157:117–132
Ramana LN, Sharma S, Sethuraman S, Ranga U, Krishnan UM (2014) Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. Biochim Biophys Acta 1840:476–484
Rao KS, Reddy MK, Horning JL, Labhasetwar V (2008) TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29(33):4429–4438
Sagar V, Pilakka-Kanthikeel S, Pottathil R, Saxena SK, Nair M (2014) Towards nanomedicines for neuroAIDS. Rev Med Virol 24(2):103–124
Saiyed ZM, Gandhi NH, Nair MP (2010) Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine 5:157–166
Sanmarti M, Ibáñez L, Huertas S, Badenes D, Dalmau D, Slevin M, Krupinski J, Popa-Wagner A, Jaen A (2014) HIV-associated neurocognitive disorders. J Mol Psychiatry 2(1):2
Saxena SK, Tiwari S, Nair MP (2012a) A global perspective on HIV/AIDS. Science 337(6096):798
Saxena SK, Tiwari S, Nair MP (2012b) Nanotherapeutics: emerging competent technology in neuroAIDS and CNS drug delivery. Nanomedicine (Lond) 7(7):941–944
Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P (2011) HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25(5):561–575
Senanayake TH, Warren G, Wei X, Vinogradov SV (2013) Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Control Release 167:200–209
Senanayake TH, Gorantla S, Makarov E, Lu Y, Warren G, Vinogradov SV (2015) Nanogel-conjugated reverse transcriptase inhibitors and their combinations as novel antiviral agents with increased efficacy against HIV-1 infection. Mol Pharm 12(12):4226–4236
Tauber SC, Staszewski O, Prinz M, Weis J, Nolte K, Bunkowski S, Brück W, Nau R (2016) HIV encephalopathy: glial activation and hippocampal neuronal apoptosis, but limited neural repair. HIV Med 17(2):143–151
Varghese NM, Senthil V, Saxena SK (2018) Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements. J Drug Target 26(3):195–207
Vinogradov SV, Batrakova EV, Kabanov AV (2004) Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 15:50–60
Wong HL, Chattopadhyay N, Wu XY, Bendayan R (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 18(62(4–5)):503–517
Xu Y, Kulkosky J, Acheampong E, Nunnari G, Sullivan J, Pomerantz RJ (2004) HIV-1-mediated apoptosis of neuronal cells: proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc Natl Acad Sci U S A 101(18):7070–7075
Yilmaz A, Price RW, Gisslén M (2012) Antiretroviral drug treatment of CNSHIV-1 infection. J Antimicrob Chemother 67(2):299–311
Zhang J, Li S, Li X (2009) Polymeric nano-assemblies as emerging delivery carriers for therapeutic applications: a review of recent patents. Recent Patents Nanotechnol 3:225–231
Acknowledgments
The authors are grateful to the Vice Chancellor, King George’s Medical University (KGMU), Lucknow, for the encouragement and support for this work. SK Saxena is also supported by CCRH, Government of India, and US NIH grants: R37DA025576 and R01MH085259. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Saxena, S.K., Maurya, V.K., Kumar, S., Bhatt, M.L.B. (2020). Modern Approaches in Nanomedicine for NeuroAIDS and CNS Drug Delivery. In: Saxena, S., Khurana, S. (eds) NanoBioMedicine. Springer, Singapore. https://doi.org/10.1007/978-981-32-9898-9_8
Download citation
DOI: https://doi.org/10.1007/978-981-32-9898-9_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9897-2
Online ISBN: 978-981-32-9898-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)